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Abstract
Background and methods: We report two clinical studies, one already published, performed in
patients with early and advanced chronic venous insufficiency (CVI). In both, compression therapy
and oral therapy with horse-chestnut seeds extracts (HCSE) were compared to placebo.
Results: The published study in early CVI (Grade I) showed HCSE and compression to be superior
to placebo and to be equivalent to each other in reducing lower leg volume, a measure for oedema.
In the study, in advanced CVI (Grade II and IIIa), compression appeared to be superior to placebo,
whereas HCSE was not. HCSE fared better in Grade II than in Grade IIIa patients.
These results are discussed in the light of data from an in vitro model, where HCSE has been able
to close the intercellular gaps in the venular endothelium. Not fully specified factors lead to an
opening of these gaps, resulting in oedema as well as in local coagulation and thrombosis. The
subsequent inflammation keeps these gaps open and initiates and maintains a chronic disease
process, which may be the starting point of CVI.
Conclusion: Due to its ability to close the venular endothelial gaps, HCSE seems to be a suitable
and protecting therapy during the early stages of CVI. In later more severe stages compression
therapy is indicated. Taking into account the observed negative impact of compression on quality
of life, pharmacological CVI therapy should start early to avoid progress and to spare patients
compression therapy.
Introduction
Chronic venous insufficiency (CVI) is a common disease;
approx. 25% of the Western European population suffer
from it. CVI is no minor disorder; because of its chronic
character patients require long-term treatment, often in
hospital or sanatorium, including surgical intervention.
In the end symptoms often force them to retire prema-
turely, with severe personal and social restrictions [1–4].
In Germany alone, the economical damage caused by
CVI is estimated at several billion Mark per year [5]. Fre-
quently CVI is still regarded a physical or mechanical dis-
order. Varicosis, thrombosis, and/or increased
haemostatic pressure following standing or sitting over
long periods lead to insufficiently closing venous valves.
This results in haemodynamic alterations and a reduced,
or even reversed, venous blood flow. The reduced drain-
age of venous blood and peripheral venous hypertension
lead to chronic hypoxia of the surrounding tissues, espe-
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tom when venous blood flow decompensates, inhibit
microcirculation. They lead, in the course of the disease,
to inflammatory reactions of the hypodermis, followed
by the characteristic signs of stasis-induced dermatitis
like sclerosis and atrophia. End stage of the disease are
badly healing crural ulcers. The focus of classical therapy
are larger veins as the putative origin of venous disease,
with compression therapy as the gold standard [6].
Because of their anti-inflammatory, anti-oedematous,
and venotonic properties, horse-chestnut extracts (HCE)
or horse-chestnut seeds extracts (HCSE), standardised
to aescin, have been studied extensively in preclinical
models of CVI and in patients with the disease. A com-
prehensive overview of the current knowledge on aescin
has been compiled by Sirtori; the review includes exten-
sive data on the mechanism of action and on the clinical
properties of the drug [7].
We report seemingly conflicting clinical data from two
studies with HCSE in patients with CVI. Both studies
were performed to compare the efficacy of HCSE with
that of compression therapy on the reduction of lower leg
volume. The studies had a similar design and included a




The first multicentre study [8] included patients pre-
dominantly with CVI Grade I according to the classifica-
tion of Widmer and Marshall [9,10]1 (See Competing
Interests). Following an a priori created random list, pa-
tients were randomised into a placebo group, a compres-
sion group, and a group receiving one capsule of HCSE,
standardised to 50 mg aescin, twice daily (Venostasin®
retard, Klinge Pharma, Munich, Germany). The patients
of the compression group received a diuretic (25 mg hy-
drochlorothiazide/50 mg triamterene) once daily during
the first treatment week to enable the application of op-
timum fitting stockings.
The study was double-blind regarding allocation to
HCSE or placebo and open regarding allocation to the
compression group. The treatment phase of 12 weeks
was preceded by a 2-week placebo run-in phase.
The main efficacy parameter was change of lower leg vol-
ume, determined by water replacement plethysmometry.
Lower leg volume was determined at baseline and after
4, 8, and 12 weeks of therapy.
Results
Of the 240 patients recruited, the compression group
comprised 99 patients, the HCSE group 95 patients, and
the placebo group 46 patients.
In the placebo group lower leg volume increased slightly
(9 ± 11 ml; mean ± standard error of the mean) during the
first four weeks of therapy and remained at that level un-
til study end (10 ± 15 ml). The patients of the compres-
sion group experienced a quick and large improvement
(45 ± 8 ml) during the first month of therapy, which was
probably influenced by the use of the diuretic during the
first week of the study. This improvement was main-
tained until study end (47 ± 8 ml). In the HCSE group
lower leg volume decreased continually (17 ± 9 ml at
week 4, 27 ± 10 ml at week 8) and reached practically the
same volume reduction as the compression group at the
final examination (44 ± 11 ml; see Figure 1, left columns).
The differences between placebo and the two active
treatment groups were significant (compression: p =
0.002; HCSE: p = 0.005). Also the test on equivalence/
non-relevant inferiority of HCSE vs. compression thera-
py was significant (p = 0.001).
The patients in the compression group showed signifi-
cantly worse quality of life scores than HCSE patients in
the parameters "reduction of well-being", "limitation of
normal daily activities", "limitation of working ability",
"limitation of leisure activities", and "limitation of enjoy-
ment of life". Compression generally was even (non-sig-
nificantly) worse than placebo in these parameters.
In this study, the incidence of adverse events or adverse
drug reactions between treatment groups was not signif-
icantly different. No serious adverse drug reactions ap-
peared. Adverse drug reactions of the gastrointestinal
tract were somewhat more frequent in the HCSE group
(5 events of nausea, heartburn, or fullness in 4 patients =
Figure 1
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2 patients = 2%).
Clinical study #2
Patients and methodology
A second randomised, multicentre study included pa-
tients with CVI Grade II and Grade IIIa [C Diehm, C
Schmidt. Venostasin® retard gegen Plazebo und Kom-
pression bei Patienten mit CVI II/IIIA. Final Study Re-
port. Klinge Pharma GmbH, Munich, Germany. 21
November 2000]. Patients who had received therapy
with vein drugs during the preceding 6 weeks and pa-
tients with oedemas of non-venous origin were excluded.
Also in this study, an a priori created random list ran-
domised patients blockwise to HCSE therapy (50 mg
aescin twice daily, Venostasin® retard, Klinge Pharma,
Munich, Germany), to compression therapy after a one
week course of diuretic, and to placebo. The study was
double-blind regarding allocation to HCSE or placebo
and open regarding allocation to the compression group.
The therapy phase was preceded by a two-week placebo
wash-out. Treatment lasted for 16 weeks. A 2-week fol-
low-up period after the treatment phase allowed an esti-
mate whether treatment effects were maintained.
Lower leg volume was determined by plethysmometry at
baseline, at weeks 4, 8, 12, and 16 of therapy, and twice
during the follow-up period. Main efficacy criterion was
the reduction of lower leg volume between start of thera-
py (Week 0) and end of therapy (Week 16). An a priori or-
dered set of hypotheses (comparison of HCSE to placebo
– comparison of compression to placebo – comparison
of HCSE to compression) was tested with modified U-
tests at an α-level of 0.05.
One secondary efficacy criterion was a subjective symp-
toms score computed from the symptoms heaviness, dis-
tension, distension pain, feeling of swelling, tiredness in
the leg, itching, leg cramps, paraesthesia, plantar burn-
ing, and unspecific subjective complaints (range from
10=healthy to 50=maximum expression of symptoms).
Quality of Life served as a further secondary parameter.
It was determined using the "Fragebogen zur Leben-
squalität bei Venenerkrankungen" FLQA, developed by
the Dermatological University Hospital of the Albert-
Ludwigs-University in Freiburg, Germany.
The sample size calculation assumed a standardised leg
volume difference of 0.5 between HCSE and placebo and
a standardised difference of 0.35 as the equivalence
range for the comparison of HCSE and compression.
This resulted in a total required patient number of 350
(140 each for the active treatment groups and 70 for the
placebo group).
Results
355 patients were included in this study. The compres-
sion group comprised 142 patients, the HCSE group 143
patients, and the placebo group 70 patients. Most pa-
tients suffered from CVI Grade II (n = 284), fewer from
CVI Grade IIIa (n = 71). No relevant inhomogeneities be-
tween treatment groups were seen.
Both active therapy groups showed a monotonous reduc-
tion of lower leg volume during the treatment phase,
whereas the placebo group did not.
Mean decrease (± standard deviation) from start to end
of therapy was 89 ± 122 ml in the compression group and
18 ± 75 ml in the HCSE group. The placebo patients
showed a mean increase of lower leg volume of 2 ± 82 ml.
After the end of therapy, i.e. during the two-week follow-
up phase, an increase in lower leg volume was observed,
more in the compression group (50 ml = 56% of im-
provement at Week 16) than in the HCSE group (8 ml =
44% of improvement at Week 16). In the compression
and in the HCSE groups, volumes at the end of the study
were still considerably below the starting values, indicat-
ing some persistence of effects. The placebo group had
exactly reached its starting point again.
Compression was significantly superior to placebo (p <
0.001), whereas HCSE was not (p = 0.115). Only in the
per-protocol population, consisting of 286 patients,
HCSE also demonstrated a significant superiority to pla-
cebo (p = 0.018).
The subjective symptoms evaluation at study end fa-
voured HCSE over compression. The difference, howev-
er, did not reach statistical significance (reduction of
total symptom score for compression: 4.56 ± 5.77; for
HCSE: 4.94 ± 6.82; higher numbers indicate superiori-
ty).
As in the study reported above [8], also here HCSE
showed more favourable results than compression in the
quality of life parameters. Compression was worst of the
three treatment groups in four of seven subscales and
best in only one. HCSE, on the other hand, was best in
three of the subscales. A complete statistical evaluation
of this secondary endpoint was not performed.
A subgroup analysis of CVI grades showed that Grade II
patients better responded to HCSE than Grade IIIa pa-
tients (volume reduction: 20 ± 77 ml vs. 8 ± 63 ml; see
Figure 1, middle and right columns). Compression, onPage 3 of 5
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grade (volume reduction: 128 ± 132 ml vs. 79 ± 119 ml).
The incidence of adverse events between the groups in
this study was not significantly different. Gastrointesti-
nal adverse events were more frequent in the HCSE
group (15% of patients affected) than in the compression
(7%) or in the placebo group (9%; p = 0.09; Chi2 test).
These were practically exclusively cases of gastroenteri-
tis, heartburn, nausea, vomiting, diarrhoea, and abdom-
inal pain or cramps. Two cases of constipation and three
cases of dry mouth occurred solely in the HCSE group.
Absolute incidence of adverse events seems higher than
in Study #1, but is caused by non-related adverse events;
these cases were excluded from the calculation of inci-
dence in Study #1. No serious adverse drug reactions oc-
curred.
Discussion
Other than Study #1, Study #2 could not prove the equiv-
alence of HCSE and compression in patients with CVI.
We assume that this is related to differences in patient
populations. Whereas Study #1 included patients in the
very early stages of CVI (Grade I), patients with ad-
vanced CVI were recruited (Grades II and IIIa) for Study
#2. Lower CVI grades seem to be more suitable for ther-
apy with HCSE. Figure 1 combines the results from both
studies and illustrates these findings.
When interpreted in the light of a recent publication by
Nees et al. [11], theses findings become plausible. Nees
focuses on the role of the smaller vessels and their en-
dothelium, as opposed to the venous valves, as the start-
ing point for CVI.
The venular endothelium possesses a unique property,
which gives it a specific role in the development of CVI.
It is, unlike the endothelium of other vessels, a contrac-
tile tissue actively regulating the width of its intercellular
gaps. Especially inflammatory mediators open these
gaps [11,12].
Opening of the venular gaps leads to an outflow of blood
and plasma components to the surrounding interstitial
tissues and forms the microscopic correlate to the oede-
ma observed clinically. Thrombogenic factors, e.g. tissue
factors, induce interstitial inflammation and thrombo-
sis, which spread to the venular lumen, possibly via the
open gaps, reducing or cutting off perfusion. This inflam-
mation may maintain the opening of the venular gaps,
thus resulting in a circulus vitiosus, a chronic situation.
Thrombocytes, polymorphonuclear granulocytes, T-
lymphocytes, and monocytes are attracted to the site of
inflammation and secrete aggressive oxidative or hydro-
lytic enzymes. Due to the reduced blood flow and damage
in the venular endothelium they are insufficiently diluted
[11].
This scenario may also occur in the vasa venorum, i.e. the
supply vessels of the larger veins [13]. This is especially
relevant for the promotion to the later stages of CVI. Mi-
crothrombi and inflammation of the venules, in the di-
rect neighbourhood of the larger veins, may compromise
the normal metabolism of venous wall structures, e.g. of
the venous valves, eventually leading to their destruc-
tion. Histological evaluation of veins from later stages of
CVI supports this hypothesis [14,15].
It remains still unclear which factors lead to an opening
of the venular gaps in the first place. Hypotheses include
immunological attacks of unknown origin, hypoxia, nu-
tritive or toxic causes, infections, and acquired or genetic
metabolic factors [7,11,16].
In an attempt to find causative forms of therapy for CVI,
Nees et al. evaluated the influence of horse-chestnut
seeds extracts (HCSE) on the contractility of the venular
endothelial cells [11]. They examined the permeability of
guinea pig venular endothelium to water applied under
pressure (hydraulic conductivity). Application of poly-
morphonuclear granulocytes and activated thrombo-
cytes to the endothelial cells increased their hydraulic
conductivity by a factor of approximately 15 vs. control.
This reflected the opening of the endothelial gaps, which
could also be observed directly by scanning electron mi-
croscopy.
The parallel addition of HCSE inhibited the increase in
conductivity in a dose dependant manner and almost
completely in a concentration of 0.01 or 0.1 mg/ml (de-
pending on extract used). The addition of the extracts,
ten minutes after the polymorphonuclear granulocytes
and thrombocytes, even restituted the increased conduc-
tivity almost to baseline values. These effects were ob-
served and verified also by scanning electron
microscopy. These findings were replicable also in hu-
man venular endothelium [Nees, personal communica-
tion].
HCSE required the presence of and probably the binding
to serum proteins to show an effect (serum proteins
alone did not show any effect and were used as a negative
control). Possibly serum concentrations of free HCSE in
man do not correspond to therapeutic efficacy [11].
Conclusion
We conclude that in early stages of CVI, when the veins
and their wall structures have not yet suffered any per-
manent damage, pharmacological methods may be suffi-
cient to interact with the disease process. Closure of thePage 4 of 5
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If venules and surrounding tissues have not yet been per-
manently damaged they have a chance to regenerate.
Also in the later stages of CVI, HCSE may still close the
venular endothelial gaps and thus can reduce oedema to
some extent, as shown in Study #2 (Figure 1). At this
time, however, the disease process has already involved
the larger veins, with irreversible damage.
Adequate therapy in this stage of CVI is compression. It
increases blood velocity by mechanically reducing the
cross-section of the larger veins. Additionally the in-
creased perivascular pressure inhibits the outflow of
blood and plasma factors from the endothelial venular
gaps, which reduces contact with tissue factor and thus
the initial steps of coagulation and thrombosis [11,17,18].
Nevertheless compression cannot restitute destroyed ve-
nous structures, but remains a mainly symptomatic ther-
apy. Especially when taking into account the reduced
quality of life under compression therapy, patients in the
early stages of CVI should be offered pharmacological
treatment rather than to wait until the only help is com-
pression.
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1 (See Competing Intrests) Grade I: Lateral phlebectasia of the
feet (corona phlebectatica paraplantaris) and tendency
for oedema
Grade II: Additionally different forms of trophic derma-
tosis like hyperpigmentation, hyperkeratosis, dermato-
sclerosis
Grade IIIa: Healed crural ulcer
Grade IIIb: Non-healed crural ulcer
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